Hyperbaric Oxygen Therapy Improves Brain Function in Patients With Cognitive Decline After COVID-19 Infection.
NCT ID: NCT05715801
Last Updated: 2023-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
80 participants
INTERVENTIONAL
2023-01-29
2024-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Hyperbaric Oxygen and Neuropsychological Therapy in Cognitive Function Following Traumatic Brain Injury
NCT03900182
Treatment of Traumatic Brain Injury With Hyperbaric Oxygen Therapy
NCT00810615
Measuring Cognitive Enhancement During Hyperbaric Oxygen Treatments
NCT04358796
Hyperbaric Oxygen Therapy for Cognition in Diabetic Elderly at High Dementia Risk
NCT03036254
Hyperbaric Oxygen Therapy for Mild Cognitive Impairment
NCT02085330
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After the intervention, the improvement of hyperbaric oxygen on cognition, fatigue, sleep disorders, anxiety and depression, and other clinical manifestations was observed. The neurologic function of hyperbaric oxygen in the treatment of patients with cognitive decline after SARS-CoV-2 infection was also evaluated from imaging and electrophysiological multi-dimensional indexes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
hyperbaric oxygen therapy
Ten sessions of hyperbaric oxygen therapy were completed within 4 weeks of enrollment.
hyperbaric oxygen therapy
The hyperbaric oxygen group was given 60 minutes of pure oxygen under 2ATA (Atmosphere Absolute, ATA) and 5 minutes of rest in between.
conventional oxygen therapy
Ten sessions of conventional oxygen therapy were completed within 4 weeks after enrollment.
conventional oxygen therapy
Conventional oxygen therapy group breathed 27% oxygen at 1.03 ATA for 60 minutes. (The chamber pressure was increased to 1.2ATA with circulating air noise for the first 5 minutes of the experiment, then reduced to 1.03 ATA for the next 5 minutes.)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
hyperbaric oxygen therapy
The hyperbaric oxygen group was given 60 minutes of pure oxygen under 2ATA (Atmosphere Absolute, ATA) and 5 minutes of rest in between.
conventional oxygen therapy
Conventional oxygen therapy group breathed 27% oxygen at 1.03 ATA for 60 minutes. (The chamber pressure was increased to 1.2ATA with circulating air noise for the first 5 minutes of the experiment, then reduced to 1.03 ATA for the next 5 minutes.)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjective cognitive decline after SARS-CoV-2 infection
* SARS-CoV-2 nucleic acid/antigen test negative.
Exclusion Criteria
* Cognitive decline can be explained by other diseases
* Conditions that researchers consider unsuitable for clinical trials.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital of Zhejiang Chinese Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jiannong Wu, M.D.
Role: STUDY_CHAIR
First Affiliated Hospital of Zhejiang Chinese Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
First Affiliated Hospital of Zhejiang Chinese Medical University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-KLS-018-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.